A Prospective Clinical Evaluation of the Total Vascular Access (TVA) FLEX-1 Device Protocol FLEX-1-001
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02119845 |
Recruitment Status :
Completed
First Posted : April 22, 2014
Last Update Posted : April 22, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Kidney Disease (CKD) | Device: Endovascular AVF (EndoAVF) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 16 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Prospective Clinical Evaluation of the TVA FLEX-1 Device Protocol FLEX-1-001 |
Study Start Date : | August 2012 |
Actual Primary Completion Date : | April 2013 |
Actual Study Completion Date : | April 2013 |
Arm | Intervention/treatment |
---|---|
Experimental: Endovascular AVF (EndoAVF)
The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access.
|
Device: Endovascular AVF (EndoAVF)
The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access.
Other Name: FLEX |
- Adverse Events [ Time Frame: 6 months ]The safety of the FLEX-1 system based on the overall complication rates derived from adverse event data.
- Access Functionality [ Time Frame: 6 Months ]The functionality of the AVF will be measured based on use of the AVF with two needles for at least 75% of dialysis sessions over a 4-week period following at least a one month maturation period.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Eligible for a native surgical arteriovenous fistula, as determined by the treating physician.
- Adult (age >18 years old).
- Advanced chronic kidney disease (CKD), stage 4 or 5 electing for hemodialysis.
- Written informed consent obtained

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02119845
Paraguay | |
Italian Hospital | |
Asuncion, Paraguay, 1001-1925 |
Principal Investigator: | Adrian Ebner, MD | Italian Hospital |
Responsible Party: | TVA Medical Inc. |
ClinicalTrials.gov Identifier: | NCT02119845 |
Other Study ID Numbers: |
FLEX-1-001 |
First Posted: | April 22, 2014 Key Record Dates |
Last Update Posted: | April 22, 2014 |
Last Verified: | April 2014 |
Chronic kidney disease Arteriovenous fistula (AVF) Hemodialysis Vascular access Endovascular AVF (EndoAVF) |
Kidney Diseases Renal Insufficiency, Chronic Urologic Diseases Renal Insufficiency |